Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).

Adult Feasibility Studies Female Humans Immunosuppressive Agents / therapeutic use Male Multiple Sclerosis / drug therapy Multiple Sclerosis, Relapsing-Remitting / chemically induced Pharmacovigilance Prospective Studies
Disease modifying therapy Multiple sclerosis Pharmacovigilance Safety Treatment associated risk

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 08 03 2022
revised: 12 05 2022
accepted: 16 05 2022
pubmed: 1 6 2022
medline: 29 6 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Clinical trial populations do not fully reflect routine practice. The power of routinely collected data to inform clinical practice is increasingly recognised. The OPTIMISE:MS pharmacovigilance study is a prospective, pragmatic observational study, conducted across 13 UK MS centres. Data were collected at the time of routine clinical visits. The first participant was recruited on 24th May 2019; data were extracted on 11th November 2021. 2112 participants were included (median age 44.0 years; 1570 (72%) female; 1981 (94%) relapsing-remitting MS). 639 (30%) were untreated at study entry, 205 (10%) taking interferon beta/copaxone, 1004 (47%) second/third generation DMT first line and 264 (13%) had escalated from a platform DMT. 342 clinical events were reported, of which 108 infections. There was an increased risk of adverse events in people taking second/third generation DMT (RR 3.45, 95%CI 1.57-7.60, p<0.01 vs no DMT). Unadjusted Poisson regression demonstrated increased incident adverse events in people taking natalizumab (IRR 5.28, 95%CI 1.41-19.74, p<0.05), ocrelizumab (IRR 3.24, 95%CI 1.22-8.62, p<0.05), and GA biosimilar (Brabio) (IRR 4.89, 95%CI 1.31-18.21, p<0.05) vs no DMT. Routinely collected healthcare data can be used to evaluate DMT safety in people with MS. These data highlight the potential of pragmatic studies to guide understanding of risks and benefits associated with DMT.

Sections du résumé

BACKGROUND BACKGROUND
Clinical trial populations do not fully reflect routine practice. The power of routinely collected data to inform clinical practice is increasingly recognised.
METHODS METHODS
The OPTIMISE:MS pharmacovigilance study is a prospective, pragmatic observational study, conducted across 13 UK MS centres. Data were collected at the time of routine clinical visits. The first participant was recruited on 24th May 2019; data were extracted on 11th November 2021.
RESULTS RESULTS
2112 participants were included (median age 44.0 years; 1570 (72%) female; 1981 (94%) relapsing-remitting MS). 639 (30%) were untreated at study entry, 205 (10%) taking interferon beta/copaxone, 1004 (47%) second/third generation DMT first line and 264 (13%) had escalated from a platform DMT. 342 clinical events were reported, of which 108 infections. There was an increased risk of adverse events in people taking second/third generation DMT (RR 3.45, 95%CI 1.57-7.60, p<0.01 vs no DMT). Unadjusted Poisson regression demonstrated increased incident adverse events in people taking natalizumab (IRR 5.28, 95%CI 1.41-19.74, p<0.05), ocrelizumab (IRR 3.24, 95%CI 1.22-8.62, p<0.05), and GA biosimilar (Brabio) (IRR 4.89, 95%CI 1.31-18.21, p<0.05) vs no DMT.
CONCLUSIONS CONCLUSIONS
Routinely collected healthcare data can be used to evaluate DMT safety in people with MS. These data highlight the potential of pragmatic studies to guide understanding of risks and benefits associated with DMT.

Identifiants

DOI: 10.1016/j.msard.2022.103894 PMID: 35636271
pubmed: 35636271
pii: S2211-0348(22)00405-9
doi: 10.1016/j.msard.2022.103894
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

103894

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Ruth Dobson (R)

Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK; Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK. Electronic address: ruth.dobson@qmul.ac.uk.

Matthew Craner (M)

Department of Neurology, John Radcliffe Hospital NHS Trust, Oxford, UK; Department of Neurology, Frimley Park Health Foundation NHS Trust, Frimley, UK.

Ed Waddingham (E)

Department of Brain Sciences, Imperial College London and UK Dementia Research Institute, Imperial College London, London, UK.

Aleisha Miller (A)

Department of Brain Sciences, Imperial College London and UK Dementia Research Institute, Imperial College London, London, UK.

Jayant Pindoria (J)

Department of Brain Sciences, Imperial College London and UK Dementia Research Institute, Imperial College London, London, UK.

Ana Cavey (A)

Department of Neurology, John Radcliffe Hospital NHS Trust, Oxford, UK.

Camilla Blain (C)

Department of Neurology, St Georges Hospital NHS Trust, London, UK.

Gabriele De Luca (G)

Department of Neurology, John Radcliffe Hospital NHS Trust, Oxford, UK.

Nikos Evangelou (N)

Nottingham University Hospitals NHS Trust, Nottingham, UK.

Helen Ford (H)

Centre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Paul Gallagher (P)

Queen Elizabeth University Hospital, Glasgow, UK.

Katila George (K)

Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Ruth Geraldes Ramos Dias (R)

Department of Neurology, John Radcliffe Hospital NHS Trust, Oxford, UK.

Paula Harman (P)

Department of Neurology, Southend Hospital, Westcliff-on-Sea, UK.

Jeremy Hobart (J)

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK; Department of Neurology, University Hospitals Plymouth NHS Trust, Plymouth, UK.

Tanya King (T)

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK; Department of Neurology, University Hospitals Plymouth NHS Trust, Plymouth, UK.

Ruth Linighan (R)

Department of Neurology, John Radcliffe Hospital NHS Trust, Oxford, UK.

Niall MacDougall (N)

Neurology Department, Hairmyres Hospital, East Kilbride, UK; Neurology Department, Institute of Neurological Sciences, Glasgow, UK.

Monica Marta (M)

Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK; Department of Neurology, Southend Hospital, Westcliff-on-Sea, UK.

Stephanie Mitchell (S)

Department of Neurology, Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK.

Richard Nicholas (R)

Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

David Rog (D)

Department of Neurology, Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust, Salford, UK.

Antonio Scalfari (A)

Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Neil Scolding (N)

Department of Neurology, Southmead Hospital NHS Trust, Bristol, UK; Department of Neurosciences, University of Bristol, Bristol, UK.

Stewart Webb (S)

Queen Elizabeth University Hospital, Glasgow, UK.

Sarah White (S)

Department of Neurology, St Georges Hospital NHS Trust, London, UK.

Judith Wilton (J)

Department of Neurology, Frimley Park Health Foundation NHS Trust, Frimley, UK.

Carolyn Young (C)

The Walton Centre, Liverpool, UK.

Paul M Matthews (PM)

Department of Brain Sciences, Imperial College London and UK Dementia Research Institute, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Evaluating the feasibility of a real world...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études de faisabilité › Evaluating the feasibility of a real world...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evaluating the feasibility of a real world...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Evaluating the feasibility of a real world...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Evaluating the feasibility of a real world...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Sclérose en plaques récurrente-rémittente › Evaluating the feasibility of a real world...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Pharmacovigilance › Evaluating the feasibility of a real world...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Evaluating the feasibility of a real world...